Author name: li6230933@gmail.com

Hechi Vice Mayor Chen Zhijie toured Tianming Pharmaceutical’s facilities, praising its R&D strength and the “Jinan R&D + Hechi production” model.

This non-peptide GLP-1 receptor agonist, now in late-stage clinical trials, is redefining possibilities for diabetes and obesity treatment. Let’s unpack what makes it distinctive from both lab bench and manufacturing perspectives.